Brief: Crescita Therapeutics Says U.S. FDA Approved Enhanced Formulation Of Pliaglis
05/11/2019 23:33
Nov 5 (Reuters) - Crescita Therapeutics Inc CTX.TO :
* U.S. FOOD AND DRUG ADMINISTRATION APPROVES ENHANCED
FORMULATION
OF PLIAGLIS®
* CRESCITA THERAPEUTICS INC - U.S. PATENT COVERING ENHANCED
FORMULATION WITH EXTENDED PROTECTION TO 2031, IS IN PROCESS OF
BEING ADDED TO ORANGE BOOK
Source text for Eikon: ID:nCNW9Hl9fa
Further company coverage: CTX.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Crescita Therapeutics
See all newsBrief: Crescita Therapeutics Obtains Shareholder Approval To Be Acquired By Clinactiv Holdings
Canada's Crescita Q1 revenue rises on manufacturing growth
Canada's Crescita Q4 revenue falls on prior-year one-time reimbursement
Brief: Crescita Reports Q4 And Fiscal 2025 Results
Brief: Crescita Announces Definitive Agreement To Be Acquired By Clinactiv Holdings In An All-Cash Transaction At A Significant Premium